Abstract
The fight against obesity is largely based on recommendations about lifestyle and therapies to initiate weight loss and, hopefully, to achieve and maintain an ideal weight. The failure of this approach is witnessed by the steady increasing rates of obesity worldwide. Lifestyle modifications yield mild weight loss with poor results in the long-term. The pharmaceutical industry is engaged to produce the best anti-obesity drugs, and this market is projected to grow massively. Guidelines on pharmacological and surgical approach to obesity are continuously developed, taking into account that benefits are counterbalanced by high costs, are limited to the period of drug intake, and potential adverse effects are possible, such as pancreatitis, gastroparesis, and bowel obstruction. Meantime, people living with obesity might simply think that taking the “magic pill” or undergoing bariatric surgery can change their life. In the long term, this tendency might lead to scarce cost-effectiveness, increasing adverse effects and inequities in the most vulnerable age classes. Furthermore, the main actors responsible for generating an obesogenic world will continue undisturbed to produce negative effects. Obesity is not only generated from voluntary individual behaviors, and no guideline can truly counteract the detrimental effects of environmental factors driving the progressive rise of obesity globally. Unsustainable food production, packaging and marketing, environmental pollution, widely diffused endocrine disrupting chemicals, and climate change are largely neglected by health professionals and generate food insecurity and malnutrition. The complexity of obesity cannot be managed only pointing to individual responsibilities of people living with obesity. There is a missing link here, and this war cannot be won in the absence of effective primary prevention measures involving changes in food production and marketing, and decreased release of toxic chemicals into the environment.
Data availability
Not applicable.
References
Di Ciaula A, Portincasa P (2021) The role of environmental pollution in endocrine diseases. Endocrinology and systemic diseases. Springer, Cham, pp 435–65
Di Ciaula A, Portincasa P (2019) Diet and contaminants: driving the rise to obesity epidemics? Curr Med Chem 26:3471–3482
Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804–814
Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR et al (2015) Genetic studies of body mass index yield new insights for obesity biology. Nature 518:197–206
Portincasa P, Di Ciaula A, Bonfrate L, Stella A, Garruti G, Lamont JT (2023) Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations. Intern Emerg Med 18:1897–1918
Bhaskaran K, Douglas I, Forbes H, dos Santos Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 384:755–65
OECD (2019) The Heavy Burden of Obesity: The Economics of Prevention OECD Health Policy Studies. OECD, Paris
Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD (1989) Treatment of obesity by very low-calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 13(Suppl 2):39–46
Singh N, Stewart RAH, Benatar JR (2019) Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open 9:e029966
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 24:1553–1564
Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY et al (2024) continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331:38–48
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (2023) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330:1795–1797
Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF et al (2023) Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. https://doi.org/10.1542/peds.2022-060640
Nguyen T, Wong E, Cope R (2023) Evaluating the efficacy and pharmacoeconomics of semaglutide and tirzepatide in the setting of obesity. Am J Ther 30:e347–e352
Lim F, Bellows BK, Tan SX, Aziz Z, Woo Baidal JA, Kelly AS, Hur C (2023) Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents. JAMA Netw Open 6:e2329178
Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR et al (2019) The global syndemic of obesity, undernutrition, and climate change: the lancet commission report. Lancet 393:791–846
Harris JL, Taillie LS (2023) More than a nuisance: implications of food marketing for public health efforts to curb childhood obesity. Annu Rev Public Health. https://doi.org/10.1146/annurev-publhealth-090419-102616
Alrubaian F, Mulla Z (2023) Governments policy measures to address obesity among adults: a scoping review of the global evidence. Lancet 402(Suppl 1):S20
Harnack L, Oakes JM, Elbel B, Beatty T, Rydell S, French S (2016) Effects of subsidies and prohibitions on nutrition in a food benefit program: a randomized clinical trial. JAMA Intern Med 176:1610–1618
Heindel JJ, Alvarez JA, Atlas E, Cave MC, Chatzi VL, Collier D et al (2023) Obesogens and obesity: state-of-the-science and future directions summary from a healthy environment and endocrine disruptors strategies workshop. Am J Clin Nutr 118:329–337
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Di Ciaula, A., Portincasa, P. Contrasting obesity: is something missing here?. Intern Emerg Med 19, 265–269 (2024). https://doi.org/10.1007/s11739-024-03559-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-024-03559-x